» Articles » PMID: 30112419

Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls

Overview
Publisher Cell Press
Date 2018 Aug 17
PMID 30112419
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Although the clinical use of recombinant adeno-associated virus (rAAV) vectors is constantly increasing, the development of suitable quality control methods is still needed for accurate vector characterization. Among the quality criteria, the titration of infectious particles is critical to determine vector efficacy. Different methods have been developed for the measurement of rAAV infectivity , based on detection of vector genome replication in -complementing cells infected with adenovirus, detection of transgene expression in permissive cells, or simply detection of intracellular vector genomes following the infection of indicator cells. In the present study, we have compared these methods for the titration of infectious rAAV8 vector particles, and, to assess their ability to discriminate infectious and non-infectious rAAV serotype 8 particles, we have generated a VP1-defective AAV8-GFP vector. Since VP1 is required to enter the cell nucleus, the lack of VP1 should drastically reduce the infectivity of rAAV particles. The AAV8 reference standard material was used as a positive control. Our results demonstrated that methods based on measurement of rAAV biological activity (i.e., vector genome replication or transgene expression) were able to accurately discriminate infectious versus non-infectious particles, whereas methods simply measuring intracellular vector genomes were not. Several cell fractionation protocols were tested in an attempt to specifically measure vector genomes that had reached the nucleus, but genomes from wild-type and VP1-defective AAV8 particles were equally detected in the nuclear fraction by qPCR. These data highlight the importance of using suitable controls, including a negative control, for the development of biological assays such as infectious unit titration.

Citing Articles

Development of cell lines with increased susceptibility to diverse adeno-associated viral vectors to enable potency assays.

Zengel J, Esterman E, Ponnuswami A, Wall N, Carette J Mol Ther Methods Clin Dev. 2025; 33(1):101416.

PMID: 40008089 PMC: 11851225. DOI: 10.1016/j.omtm.2025.101416.


Microfluidic digital focus assays for the quantification of infectious influenza virus.

Srimathi S, Ignacio M, Rife M, Tai S, Milton D, Scull M Lab Chip. 2025; .

PMID: 39907221 PMC: 11796355. DOI: 10.1039/d4lc00940a.


Crucial aspects for maintaining rAAV stability.

Lengler J, Gavrila M, Brandis J, Palavra K, Dieringer F, Unterthurner S Sci Rep. 2024; 14(1):27685.

PMID: 39533000 PMC: 11557909. DOI: 10.1038/s41598-024-79369-0.


Characterization of AAV vectors: A review of analytical techniques and critical quality attributes.

Kontogiannis T, Braybrook J, McElroy C, Foy C, Whale A, Quaglia M Mol Ther Methods Clin Dev. 2024; 32(3):101309.

PMID: 39234444 PMC: 11372808. DOI: 10.1016/j.omtm.2024.101309.


In-Depth Comparison of Adeno-Associated Virus Containing Fractions after CsCl Ultracentrifugation Gradient Separation.

Janc M, Zevnik K, Dolinar A, Jakomin T, Stalekar M, Bacnik K Viruses. 2024; 16(8).

PMID: 39205208 PMC: 11360810. DOI: 10.3390/v16081235.


References
1.
Kronenberg S, Bottcher B, von der Lieth C, Bleker S, Kleinschmidt J . A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol. 2005; 79(9):5296-303. PMC: 1082756. DOI: 10.1128/JVI.79.9.5296-5303.2005. View

2.
Clark K, Voulgaropoulou F, Fraley D, Johnson P . Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther. 1995; 6(10):1329-41. DOI: 10.1089/hum.1995.6.10-1329. View

3.
Martin J, Frederick A, Luo Y, Jackson R, Joubert M, Sol B . Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production. Hum Gene Ther Methods. 2013; 24(4):253-69. DOI: 10.1089/hgtb.2013.046. View

4.
Gagnon K, Li L, Janowski B, Corey D . Analysis of nuclear RNA interference in human cells by subcellular fractionation and Argonaute loading. Nat Protoc. 2014; 9(9):2045-60. PMC: 4251768. DOI: 10.1038/nprot.2014.135. View

5.
Zeltner N, Kohlbrenner E, Clement N, Weber T, Linden R . Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther. 2010; 17(7):872-9. PMC: 2900506. DOI: 10.1038/gt.2010.27. View